Search
Filters
Clear All
  • 1
  • 1
  • 64

Phase

  • 2
  • 5
  • 6
  • 4
  • 45
  • 62
  • 30

Found 66 Neoplasms trials

A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

S
Sandeep Batra, MD
1 - 21
All genders
Phase 2
What is the purpose of this study?This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or …
Learn More

Biomarkers for Noninvasive respiratory support in Immunocompromised Children (BioNIC)

C
Courtney Rowan, MD
1 - 26
All genders
What is the purpose of this study?The goal of this study is to identify and validate response to therapy biomarkers for NIV respiratory support in children with ICCs. The central hypothesis is that response-to-therapy biomarkers can identify those most likely to benefit from intervention with NIV. The rationale is that …
Learn More

A first-in-human, Phase I Study to Evaluate the Safety of TTX-080, an HLA-G Antagonist, in Subjects with Advanced Solid Tumors

G
Greg Durm, MD
18 - 100
All genders
Phase 1
To assess the safety and tolerability of TTX-080
Learn More

A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients With Advanced Solid Tumors

G
Greg Durm, MD
18 - 100
All genders
This is a Phase 1, open label, multi-center study of orally administered DSP-0337 in adult subjects with advance solid tumors that are refractory to standard treatment, or for whom no effective therapy exists.
Learn More

eFT508 in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone

G
Greg Durm, MD
18 - 100
All genders
This study will evaluate the safety, tolerability, antitumor activity, and pharmacokinetics (PK) of eFT508 in patients who have initiated anti-PD-1/anti-PD-L1 monotherapy and either developed progressive disease (PD) on therapy or have undergone 12 weeks of anti-PD-1/anti-PD-L1 therapy with no evidence of partial response (PR) or complete response (CR).
Learn More

A Phase 1 Study Of Ramucirumab a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors Including CNS Tumors

J
James Croop, MD, PhD
1 - 21
All genders
The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
Learn More

A Phase II Trial of Cabozantinib With Patients With Refractory GCTs

N
Nabil Adra, MD
All genders
Phase 2
Interventional
The purpose of the CTO-IUSCCC-0752 study is to investigate the use of Cabozantinib forwith incurable, refractory germ cell tumors. Patients will be treated until evidencedisease progression, non-compliance with study protocol, unacceptable major toxicity, atubject's own request for withdrawal, or if the study closes for any reason.
Learn More

PHO-COG-CROOP-ADVL1312; A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

J
James Croop, MD, PhD
1 - 21
All genders
This phase I/II trial studies the side effects and best dose of WEE1 inhibitor MK-1775 and irinotecan hydrochloride in treating younger patients with solid tumors that have come back or that have not responded to standard therapy. WEE1 inhibitor MK-1775 and irinotecan hydrochloride may stop the growth of tumor cells …
Learn More

A Phase 1/2 Trial of VX15/2503 in Children Adolescents or Young Adults With Recurrent or Relapsed Solid Tumors

J
James Croop, MD, PhD
1 - 30
All genders
This phase I/II trial studies the side effects and best dose of anti-SEMA4D monoclonal antibody VX15/2503 (VX15/2503) and to see how well it works in treating younger patients with solid tumors that have come back after treatment, or do not respond to treatment.
Learn More

A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Adult Participants With Selected Advanced Solid Tumors

P
Patrick Loehrer, MD
18 - 100
All genders
In an unbiased CRISPR screen, RIPK1 was identified as a top gene contributing to immunotherapy resistance. In addition, RIPK1 has been reported to drive pancreatic oncogenesis. In murine models, inhibition of RIPK1 kinase activity in the pancreatic tumor microenvironment leads to the replacement of tumor-permissive myeloid infiltrates with innate cells …
Learn More
21 - 30 of 66